Avedro

Opportunities and challenges in the world of ophthalmology in 2018As another year comes to an end, five members of Ophthalmology Times Europe’s Editorial Advisory Board reflect and share their perspectives on the exciting opportunities that lie ahead for ophthalmologists in 2018, whilst also considering the potential challenges.
CXL demands continuity of careCrosslinking meets the previously unmet needs of progressive keratoconus patients and provides an opportunity to increase engagement with optometrists, explain John Berdahl, MD, and George O. Waring IV, MD.
Crosslinking showing potential for refractive correction
Crosslinking showing potential for refractive correctionPhotorefractive intrastromal cross-linking is being developed for non-invasive correction of low refractive errors.
Collagen corneal cross-linking for keratoconusThe recently approved procedure will help many with this progressive disease
Clinical implications of corneal cross-linkingNow that we have CXL , it is imperative for clinicians to incorporate new technologies that can help us achieve disease detection at the earliest clinical stage prior to onset of visual symptoms.
Treating refractive error with corneal cross-linking
Treating refractive error with corneal cross-linkingAfter much anticipation and a long wait for both clinicians and patients in need, the U.S. Food and Drug Administration (FDA) approved corneal cross-linking (CXL) in mid April. This procedure is globally considered the only method of halting the progressive family of diseases called corneal ectasias, including keratoconus.
Avedro acquires assets of IROC InnocrossAvedro has purchased the assets of IROC Innocross, a Swish company that has commercialized a cross-linking device for the treatment of keratoconus and other corneal pathologies.
FDA seeking more info on Avedro’s corneal cross-linking NDAAvedro Inc. has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for riboflavin ophthalmic solution/KXL System to treat keratoconus and corneal ectasia after refractive surgery.
FDA responds to Avedro NDAAvedro Inc. has received a complete response letter from the FDA regarding the new drug application (NDA) for its riboflavin ophthalmic solution/KXL System.